<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502616</url>
  </required_header>
  <id_info>
    <org_study_id>A3921120</org_study_id>
    <secondary_id>AS</secondary_id>
    <nct_id>NCT03502616</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)</brief_title>
  <official_title>A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if tofacitinib is safe and effective in subjects
      with active ankylosing spondylitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 26, 2018</start_date>
  <completion_date type="Anticipated">August 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment in Ankylosing Spondylitis (ASAS) 20 response</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment in Ankylosing Spondylitis (ASAS) 40 response</measure>
    <time_frame>Weeks 2,4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment in Ankylosing Spondylitis (ASAS) 20 response</measure>
    <time_frame>Weeks 2, 4, 8, 12, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment in Ankylosing Spondylitis (ASAS) 5/6 response</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ankylosing Spondylitis Disease Activity Score using C-Reactive Protein</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity C-reactive protein</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Disease Activity Score (ASDAS) clinically important improvement</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Disease Activity Index</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASDAI50 response</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Functional Index</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bath Ankylosing Spondylitis Metrology Index and its 5 components</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
    <description>5 components are Lateral Spinal Flexion, Tragus to wall distance, Lumbar flexion, Maximal Intermalleolar distance and Cervical Rotation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maastricht Ankylosing Spondylitis Enthesitis Score</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count (44)</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spinal Mobility: Chest Expansion</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
    <description>Chest expansion is measured as the difference between maximal inspiration and expiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS partial remission response at all time points</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse Events</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short-Form-36 Healthy Survey Version 2 Acute</measure>
    <time_frame>Weeks 16 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol EQ-5D Health State Profile</measure>
    <time_frame>Weeks 16 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy Fatigue</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankylosing Spondylitis Quality of Life</measure>
    <time_frame>Weeks 16 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Productivity and Activity Impairment Questionnaire Spondyloarthritis</measure>
    <time_frame>Weeks 16 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Healthcare Resource Utilization Questionnaire</measure>
    <time_frame>Weeks 16 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Disease Activity Score (ASDAS) major improvement response</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing Spondylitis Disease Activity Score Inactive disease response</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Tofacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Oral administration twice per day</description>
    <arm_group_label>Tofacitinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria
             for AS (1984).

          -  Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.

          -  Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or
             intolerant to NSAIDs.

        Exclusion Criteria:

          -  History of known or suspected complete ankylosis of the spine.

          -  Subject who has previously participated in any study of tofacitinib.

          -  History of any other rheumatic disease.

          -  Any subject with condition affecting oral drug absorption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921120&amp;StudyName=A+Phase+3%2C+Randomized%2C+Double+Blind%2C+Placebo+Controlled%2C+Study+Of+The+Efficacy+And+Safety+Of+Tofacitinib+In+Subjects+With+Active+Ankylosing+Spondylitis+%28as%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

